NCT06543381View on ClinicalTrials.gov

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

February 5, 2027

Study Completion Date

February 5, 2027

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Olutasidenib

Given PO

Trial Locations (2)

44195

NOT_YET_RECRUITING

Cleveland Clinic Cancer Center, Cleveland

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER